NewAmsterdam Pharma (NAMS) Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Does the media favor NAMS or ASND?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.65 beat Ascendis Pharma A/S's score of 0.64 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend NAMS or ASND?

NewAmsterdam Pharma currently has a consensus target price of $38.17, suggesting a potential upside of 62.07%. Ascendis Pharma A/S has a consensus target price of $192.07, suggesting a potential upside of 49.90%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Is NAMS or ASND more profitable?

NewAmsterdam Pharma has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -130.33%.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
Ascendis Pharma A/S	-130.33%	N/A	-48.77%

Which has more risk and volatility, NAMS or ASND?

NewAmsterdam Pharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Which has preferable earnings & valuation, NAMS or ASND?

NewAmsterdam Pharma has higher earnings, but lower revenue than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$14.09M	154.42	-$176.94M	N/A	N/A
Ascendis Pharma A/S	$288.08M	26.99	-$521.07M	-$8.08	-15.86

Does the MarketBeat Community prefer NAMS or ASND?

Ascendis Pharma A/S received 417 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 66.57% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
NewAmsterdam Pharma	Outperform Votes 23 100.00%	Underperform Votes No Votes
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%

Do institutionals & insiders hold more shares of NAMS or ASND?

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Ascendis Pharma A/S on 9 of the 15 factors compared between the two stocks.